164 related articles for article (PubMed ID: 2277141)
21. The role of dendritic cells in the immunopathogenesis of psoriasis.
Jariwala SP
Arch Dermatol Res; 2007 Oct; 299(8):359-66. PubMed ID: 17680257
[TBL] [Abstract][Full Text] [Related]
22. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A.
Al-Daraji WI; Grant KR; Ryan K; Saxton A; Reynolds NJ
J Invest Dermatol; 2002 May; 118(5):779-88. PubMed ID: 11982754
[TBL] [Abstract][Full Text] [Related]
23. T-cell activation is potentiated by cytokines released by lesional psoriatic, but not normal, epidermis.
Chang EY; Hammerberg C; Fisher G; Baadsgaard O; Ellis CN; Voorhees JJ; Cooper KD
Arch Dermatol; 1992 Nov; 128(11):1479-85. PubMed ID: 1359841
[TBL] [Abstract][Full Text] [Related]
24. Clinical clearing of psoriasis by 6-thioguanine correlates with cutaneous T-cell depletion via apoptosis: evidence for selective effects on activated T lymphocytes.
Murphy FP; Coven TR; Burack LH; Gilleaudeau P; Cardinale I; Auerbach R; Krueger JG
Arch Dermatol; 1999 Dec; 135(12):1495-502. PubMed ID: 10606055
[TBL] [Abstract][Full Text] [Related]
25. Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell-Th17 cell axis in psoriasis.
Lovato P; Norsgaard H; Tokura Y; Røpke MA
J Dermatol Sci; 2016 Mar; 81(3):153-64. PubMed ID: 26794805
[TBL] [Abstract][Full Text] [Related]
26. Effect of PUVA, narrow-band UVB and cyclosporin on inflammatory cells of the psoriatic plaque.
Erkin G; Uğur Y; Gürer CK; Aşan E; Korkusuz P; Sahin S; Kölemen F
J Cutan Pathol; 2007 Mar; 34(3):213-9. PubMed ID: 17302604
[TBL] [Abstract][Full Text] [Related]
27. The role of the T cell in psoriasis and the action of cyclosporin in this disease.
Fry L
Acta Derm Venereol Suppl (Stockh); 1989; 146():133-4; discussion 134-5. PubMed ID: 2609854
[No Abstract] [Full Text] [Related]
28. Cyclosporine A inhibits accessory cell and antigen-presenting cell functions of epidermal Langerhans cells.
Furue M; Katz SI
Transplant Proc; 1988 Apr; 20(2 Suppl 2):87-91. PubMed ID: 3259044
[No Abstract] [Full Text] [Related]
29. [Concepts of the mechanisms of action of cyclosporin in psoriasis. A review with guidelines on therapy].
Mrowietz U
Hautarzt; 1993 Jun; 44(6):353-60. PubMed ID: 8392987
[TBL] [Abstract][Full Text] [Related]
30. The mechanisms of action of cyclosporin A in the treatment of psoriasis.
Wong RL; Winslow CM; Cooper KD
Immunol Today; 1993 Feb; 14(2):69-74. PubMed ID: 8447934
[TBL] [Abstract][Full Text] [Related]
31. Speculations on the immunopathogenesis of psoriasis: T-cell violation of a keratinocyte sphere of influence.
Streilein JW
J Invest Dermatol; 1990 Nov; 95(5 Suppl):20S-21S. PubMed ID: 16788622
[TBL] [Abstract][Full Text] [Related]
32. Cyclosporine A in psoriasis: an immunohistological study.
Mozzanica N; Cattaneo A; Pigatto PD; Finzi AF
Transplant Proc; 1988 Jun; 20(3 Suppl 4):78-84. PubMed ID: 3260053
[No Abstract] [Full Text] [Related]
33. Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes.
Albanesi C; De Pità O; Girolomoni G
Clin Dermatol; 2007; 25(6):581-8. PubMed ID: 18021896
[TBL] [Abstract][Full Text] [Related]
34. Immunohistologic evaluation of the effect of cyclosporine treatment on the lichen planus immune infiltrate.
Mozzanica N; Cattaneo A; Legori A; Pigatto P; Finzi AF
J Am Acad Dermatol; 1991 Apr; 24(4):550-4. PubMed ID: 2033128
[TBL] [Abstract][Full Text] [Related]
35. Topical calcipotriol for psoriasis--an immunohistologic study.
Mozzanica N; Cattaneo A; Schmitt E; Diotti R; Finzi AF
Acta Derm Venereol Suppl (Stockh); 1994; 186():171-2. PubMed ID: 7915481
[TBL] [Abstract][Full Text] [Related]
36. Psoriasis in humans is associated with down-regulation of galectins in dendritic cells.
de la Fuente H; Perez-Gala S; Bonay P; Cruz-Adalia A; Cibrian D; Sanchez-Cuellar S; Dauden E; Fresno M; García-Diez A; Sanchez-Madrid F
J Pathol; 2012 Oct; 228(2):193-203. PubMed ID: 22271227
[TBL] [Abstract][Full Text] [Related]
37. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
Krueger J; Clark JD; Suárez-Fariñas M; Fuentes-Duculan J; Cueto I; Wang CQ; Tan H; Wolk R; Rottinghaus ST; Whitley MZ; Valdez H; von Schack D; O'Neil SP; Reddy PS; Tatulych S;
J Allergy Clin Immunol; 2016 Apr; 137(4):1079-1090. PubMed ID: 27059729
[TBL] [Abstract][Full Text] [Related]
38. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes.
Bata-Csorgo Z; Hammerberg C; Voorhees JJ; Cooper KD
J Clin Invest; 1995 Jan; 95(1):317-27. PubMed ID: 7529261
[TBL] [Abstract][Full Text] [Related]
39. Topical cyclosporine A inhibits the phorbol ester induced hyperplastic inflammatory response but not protein kinase C activation in mouse epidermis.
Gupta AK; Fisher GJ; Elder JT; Talwar HS; Esmann J; Duell EA; Nickoloff BJ; Voorhees JJ
J Invest Dermatol; 1989 Sep; 93(3):379-86. PubMed ID: 2570112
[TBL] [Abstract][Full Text] [Related]
40. In situ demonstration of CD40- and CD154-positive cells in psoriatic lesions and keratinocyte production of chemokines by CD40 ligation in vitro.
Pasch MC; Timár KK; van Meurs M; Heydendael VM; Bos JD; Laman JD; Asghar SS
J Pathol; 2004 Jul; 203(3):839-48. PubMed ID: 15221944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
